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Coronary artery disease (CAD) is a multifactorial disease with environmental and genetic determinants. The genetic determinants
of CAD have previously been explored by the candidate gene approach. Recently, the data from the International HapMap Project
and the development of dense genotyping chips have enabled us to perform genome-wide association studies (GWAS) on a large
number of subjects without bias towards any particular candidate genes. In 2007, three chip-based GWAS simultaneously revealed
thesigniﬁcantassociationbetweencommonvariantsonchromosome9p21andCAD.Thisassociationwasreplicatedamongother
ethnic groups and also in a meta-analysis. Further investigations have detected several other candidate loci associated with CAD.
The chip-based GWAS approach has identiﬁed novel and unbiased genetic determinants of CAD and these insights provide the
important direction to better understand the pathogenesis of CAD and to develop new and improved preventive measures and
treatments for CAD.
1.Introduction
Coronary artery disease (CAD) including myocardial infarc-
tion (MI) is a leading cause of death worldwide [1, 2].
The well-known conventional coronary risk factors include
age, male sex, hypertension, diabetes mellitus, hypercholes-
terolemia, smoking and family history, which have been
repeatedly demonstrated in multiple epidemiological studies
[3–5]. Lifestyle and environmental factors play an important
role in the pathogenesis; however, genetic predisposition is
also thought to contribute to CAD/MI since these diseases
cluster in families [6].
In the epidemiological studies using twins, the relative
hazard of death among men from CAD when one’s twin died
of CAD before the age of 55 years, as compared with the
hazard when one’s twin did not die before 55, was 8.1 for
monozygotictwinsand3.8fordizygotictwins[7].Therecent
epidemiological survey in the Framingham study showed
that parental cardiovascular disease independently predicted
future oﬀspring events [8]. In this survey, participants with
at least one parent with premature CAD had greater risk
for events with age-adjusted odds ratios (ORs) of 2.6 for
men and 2.3 for women compared with those with no
parental CAD. These results support further research into
genetic determinants of CAD risk. Elucidating the genetic
determinants would improve risk assessment and provide
better measures for prevention and treatment.
As the molecular biology and genetics had progressed,
the genetic backgrounds were explored in the several genes
which were thought to contribute to the pathogenesis of at-
herosclerosis and conventional coronary risk factors. Candi-
date gene studies tested the hypothesis that proteins known
to be involved in the pathogenesis of atherosclerosis carry
variants that aﬀect their protein functions and the risk of
developing CAD. In 1992, Cambien et al. [9]e x p l o r e da
possible association between CAD and a variation found in
the gene encoding angiotensin-converting enzyme (ACE).
The polymorphism ACE/insertion/deletion (ACE/ID) is
strongly associated with the level of the circulating enzyme.
They reported that the deletion homozygote (DD genotype),2 International Journal of Hypertension
which was associated with higher levels of circulating ACE,
is signiﬁcantly more frequent in patients with MI than in
controls.
The representative variants associated with CAD/MI
found by candidate gene approach are listed in Table 1.
However,thosecandidategeneswerenotalwaysreproducible
in multiple studies later on. One of the reasons for poor
reproducibility is that many of the study samples were
not large enough with some exceptions to identify disease-
associated genetic variants with odds ratio <2.0. In addition,
candidate gene studies only tested a single to few variants
for association with CAD and these approaches cannot
discover unknown novel variants and also cannot evaluate
how strong each variant contribute to the susceptibility to
CAD. Therefore, the candidate gene approach resulted in
only limited success in the elucidation of genetic risks for
CAD.
In parallel with candidate gene studies, other strategies
were carried out to interrogate the entire human genome
without hypotheses on which genes may be responsible for
disease risk. One of the strategies is genome-wide linkage
analysis and it is based on the Mendelian cosegregation of
a genetic marker within a family. However, great eﬀorts
h a dt ob em a d ei no r d e rt oc o l l e c ts u ﬃcient numbers
of aﬀected sibling pairs. Only a small number of studies
were successfully performed and few genetic loci (2q21-22,
Xq23-26 [10], myocyte enhancer factor-2 (MEF2A)[ 11],
arachidonate 5-lipoxygenase-activating protein (ALOX5AP)
[12], leukotriene A4 hydrolase (LTA4H)[ 13]) were detected
to be associated with CAD (Table 2). These genes had
never been suggested as causative genes before these family-
based studies, suggesting the eﬀectiveness of this approach
in detection of novel genetic determinants. However, those
associations were not always replicated. Such a family-based
study has been frequently used to identify new loci in
monogenic diseases, but the application of this strategy to
multifactorial diseases is relatively limited.
In this situation, whole genome analysis in a case-
control study design had gradually emerged around the
beginning of the 21st century. Resources including the
single nucleotide polymorphism (SNP) databases, major
technological advances in high-throughput genotyping, and
methods of data processing and statistical analysis allow
researchers to confront limitations in previous approaches.
Here, we introduce the representative genome-wide case-
control association studies in the next two sections.
2. Establishment of J-SNP Databaseand
Whole Genome Approachin Japan
Beginning in 2000, the Prime Minister’s Millennium Project
(J-SNP) was launched in Japan and about hundred thousand
SNPs located in genes or in adjacent regions that might
inﬂuence the coding sequence of the genes were identiﬁed
in Japanese population. J-SNP established a web-based
database and allowed researchers access to high quality SNP
data [14]. Genome-wide association studies using this SNP
database were performed in our country in many important
Table 1: The well-known genetic polymorphisms which are
thought to be associated with myocardial infarction or coronary
artery disease.
Location Gene name/Polymorphisms
17q23 Angiotensin-Converting Enzyme
insertion/deletion (intron 16)
1q42-q43 Angiotensinogen Met235Thr, −6G/A
3q21-q25 Angiotensin II type1 Receptor 1166A/C
8q21-q22 Aldosterone Synthase (CYP11B2)
−344T/C, Lys173Arg
14q32.1-q32.2 Bradykinin B2 receptor gene −58T/C
6p24.1 Endothelin-1 Lys198Asn
7q36 eNOS Glu298Asp, −786T/C
17q21.32 Glycoprotein IIIa P1A1/A2
5q23-31 Glycoprotein Ia 807T/C
17pter-p12 Glycoprotein Ibα Thr145Met
4q28 βﬁbrinogen −455G/A
11p11-q12 Prothrombin 20210G/A
7q21.3-q22 PAI-1 4G/5G (promoter region)
7q21.3 Paraoxonase1 Arg192Gln, Leu54Met
8p12-p11.2 Werner Helicase Gene Cys1367Arg
1p36.3 Methylenetetrahydrofolate reductase
677C/T
16q24 NADH/NADPH oxidase p22phox
242C/T, 640A/G
5q31.1 CD14 Monocyte Receptor −260C/T
11q22.3 Stromelysin (MMP3) 5A/6A (promoter
region)
20q11.2-q13.1 Gelatinase B (MMP9) −1562C/T
19q13.2 ApolipoproteinE E2/E3/E4
16q21 C h o l e s t e r y lE s t e rT r a n s f e rP r o t e i n
(CETP) Ile405Val
9q31.1 ABCA1 gene Ile823Met
3p25 PPAR-gamma Pro12Ala, Pro115Gln
20q13.11-q13.13 Prostacyclin synthase gene
The number of 9-bp (CCGCCAGCC) repeats (promoter region)
17q11.2-q21.1 MCP-1 −2518G/A
Table 2: Representative loci associated with CAD identiﬁed in the
family-based studies.
Reporter
(year) Race locus LOD score causative gene
Pajukanta
et al. [10] Finland 2q21-22 3.7 no gene identiﬁed
Xq23-26 3.5 no gene identiﬁed
Wang et al.
[11] USA 15q26 4.19 MEF2
Helgadottir
et al. [12] Iceland 13q12-13 2.86 ALOX5AP
Helgadottir
et al. [13] Iceland 17q22 NA LTA4H
NA = not available.International Journal of Hypertension 3
clinical ﬁelds including cardiovascular diseases, diabetes,
renal dysfunction and autoimmune collagen diseases.
As the ﬁrst genome-wide case-control association study
in the world, Ozaki et al. [15] used 92,788 gene-based SNP
markers and identiﬁed that the homozygosity in two SNPs
in lymphotoxin A (LTA) at 6p21 was signiﬁcantly associated
with increased risk for MI in Japanese (odds ratio (OR)
= 1.78). In vitro analyses showed that one functional SNP
(Thr26Asn) caused a twofold increase in induction of sev-
eral inﬂammation-related cell-adhesion molecules including
vascular cell adhesion molecule 1 (VCAM1) in vascular
smooth-muscle cells. Moreover, the SNP located in intron
1 of LTA enhanced the transcriptional level of LTA. These
results indicated the variants in the LTA are risk factors for
MI and implicated LTA as a novel pathogenic factor for MI.
In the same year, LTA knockout mouse was shown to be
resistant to atherosclerosis [16]. Double knockout mice of
apolipoprotein E (ApoE) and LTA (ApoE−/−LTA−/− mice)
showed less extent of atherosclerosis than ApoE−/−LTA+/+
mice, indicating LTA deteriorates atherosclerosis in vivo,
consistent with the result of the genetic association study of
LTA as a genetic risk for atherosclerotic disease.
Subsequently,theyidentiﬁedSNPsthatweresigniﬁcantly
associated with MI in lectin, galactoside-binding, soluble,
2g e n e( LGALS2)[ 17], proteasome subunit alpha type 6
gene (PSMA6)[ 18], myocardial infarction associated tran-
script (MIAT)[ 19], inter-alpha (globulin) inhibitor 3 gene
(ITIH3)[ 20] and BRCA1-associated protein gene (BRAP)
[21] mainly by functional approaches. All the six causative
genetic regions are related to inﬂammatory process in
vasculature and are thought to contribute to the process in
atherosclerotic changes through its inﬂammatory functions
and thus increase the risk of MI.
3.Chip-BasedGWASandNovelCandidate
GeneticDeterminantsfor CAD
3.1. HapMap Project. Genome-wide association studies
based on the J-SNP database (approximately 100,000 SNPs)
have detected several SNPs which had signiﬁcant association
with myocardial infarction. However, the J-SNP database
does not cover SNPs in intergene regions. In the meantime,
the International HapMap Project was conducted to create a
public genome-wide database of common SNPs and enable
systematicstudiesofcommonSNPsfortheirpotentialrolein
human disease [22, 23]. The Project analyzed DNA samples
from 90 people with European ancestry, 90 Yoruba people in
Nigeria, 44 Japanese and 45 Han Chinese and has now geno-
typed over 3.1 million SNPs in each of these populations.
However,testingalloftheseSNPsinaperson’schromosomes
would be extremely expensive. Adjacent SNPs across the
genome are correlated each other, a phenomenon known as
linkage disequilibrium and SNPs that are inherited together
were compiled into “haplotypes”. A haplotype block may
contain many SNPs, but only a few “tag” SNPs can provide
most of the information on the pattern of genetic variation
intheblock.TheHapMapprojectidentiﬁedthese“tag”SNPs
within haplotypes that uniquely identify these haplotypes.
The HapMap data allowed eﬃcient design of Chip-based
genome association studies and allowed investigators to
genotype far fewer SNPs while still retaining statistical power
to ﬁnd genetic variants related to common illness.
3.2. High throughput SNP Genotyping Platforms. The devel-
opment of dense genotyping chips enables genotyping up to
1 million SNPs on a single small chip. This chip technology
allowed genome-wide association studies (GWAS) to be per-
formed on a large numbers of subjects. Chip-based GWAS
typically involves genotyping approximately a few thousands
cases with a disease and a few thousands of controls for
about500,000tagSNPs.Sincethereare500,000comparisons
per study, there is a high potential for false positive results.
The proposed solution for that is applying the stringent
P value using the Bonferroni correction for multiple tests.
In that case, P value will be 0.05 divided by 500,000 and
that is 0.0000001 (10−7) and this stringent P v a l u ei so f t e n
termed as ‘genome-wide signiﬁcance’. The most statistically
signiﬁcant variants identiﬁed in the initial case-control
analysis are tested for replication in subsequent case-control
studies. In GWAS method, associations between SNPs and
the diseases are made free of bias of particular candidate
genes. This makes the possibility of obtaining novel and
unbiased information and provides the important direction
to better understand the pathophysiology of the disease. For
CAD, three chip-based GWAS were simultaneously reported
in 2007 and all of them showed the signiﬁcant association
between CAD and SNPs on chromosome 9p21.
3.3. 9p21 and other Chromosomal Loci Associated with
CAD/MI Detected in Chip-Based GWAS. Helgadottir et al.
enrolled a total of 4587 MI cases and 12,767 controls and
genotyped total 305953 SNPs using Illumina Hap300chip
(Illumina) [24]( Table 3). All the participants were European
descent. They identiﬁed disease association variant located
in 9p21, adjacent to the tumor suppressor genes cyclin-
dependent kinase inhibitor 2A (CDKN2A) and cyclin-
dependent kinase inhibitor 2B (CDKN2B) with great statis-
tical signiﬁcance. This region had never been estimated to be
associatedwithsusceptibilitytoMI.TheyshowedthealleleG
of the SNP rs10757278 (Figure 1) showed the strongest asso-
ciation with MI. The ORs for heterozygous and homozygous
carriers of the risk allele G were 1.26 and 1.64, respectively.
The ORs for early-onset MI (MI before the age of 50 for
males and before the age of 60 for females) are 1.49 and 2.02
for heterozygous and homozygous carriers of the risk allele,
respectively. They estimated the population attributable risk
is 21% for MI in general and 31% for early-onset cases.
The SNPs on chromosome 9p21 associated with MI are
located in the same disequilibrium block of the one which
contains CDKN2A and CDKN2B. These genes encode two
members of the inhibitors of CDK4 (Ink4) family of cyclin-
dependent kinase inhibitors, p16Ink4a and p15Ink4b,a n da
completely unrelated protein called ARF. The p16Ink4a and
p15Ink4b which activates retinoblastoma (Rb) family mem-
bers and ARF which activates p53 were shown to be upregu-
lated in cancer cells. They play a critical role in cell prolifera-
tion and aging, senescence and apoptosis [25, 26]. However,
sequencing 93 early-onset MI patients across these genes did4 International Journal of Hypertension
Human
(chr 9p21)
MTAP
CDKN2A
CDKN2B DMRTA1
Non coding CAD risk interval (58kb)
rs12555547
rs10757278
rs10757274 rs2383206
rs1333049
5kb
50kb
rs10965244
Figure 1
ANRIL
Figure 1: The 58kb non-coding CAD risk interval on chromosome 9p21.
not reveal obvious causal functional variants or variants that
could account for the correlation of rs10757278 to MI. The
linkage disequilibrium block also contains two exons of the
transcript hypothetical methylthioadenosine phosphorylase
fusionprotein mRNA,howeverthe functionalsigniﬁcanceof
the variants in this region remains to be elucidated.
McPherson et al. also identiﬁed a 58-kilobase region
on chromosome 9p21 that was consistently associated with
CAD in six independent samples consisted of 4306 cases and
20119 controls from four Caucasian populations [27]. They
identiﬁed two SNPs rs10757274 and rs2383206 on 9p21 that
are signiﬁcantly associated with incident of CAD. The risk
allele was associated with and ∼15 to 20% increase risk of
CAD in the 50% individuals who are heterozygous and ∼30
to 40% increase in the 25% who are homozygous for the
allele.
They further genotyped surrounding region of these
SNPs in detail and found that eight additional SNPs at the
locus spanning a 58-kb region were signiﬁcantly associated
with CAD. Again, the 58-kb region does not contain any
annotated genes. however, the region overlaps a newly
annotated noncoding RNA called noncoding RNA in the
INK locus (ANRIL)[ 28]. ANRIL consists of 20 exons
subjected to alternative splicing. The whole blood RNA
expression levels of short variants of ANRIL are increased
and the expression levels of the long variant are decreased
in subjects homozygous for the risk alleles. There is also
a positive correlation between transcript levels of the long
variant of ANRIL and CDKN2B [29].
The study using genetically engineered mice showed that
the deletion of orthologous 70-kb non-coding interval on
mouse chromosome 4 (chr4 70kb/ 70kbmice) highly reduced
cardiac expression of two neighboring genes CDKN2A and
CDKN2B. Primary culture of smooth muscle cells from
chr4 70kb/ 70kbmice showed increased proliferation and
diminished senescence, the features relevant to atherosclero-
sis [30]. These ﬁndings indicated the noncoding interval is
involved in the disease process via gene-regulatory eﬀects on
CDKN2A and CDKN2B.
The Wellcome Trust Case Control Consortium
(WTCCC)studywhichenrolled1926casesubjectswithCAD
and 2938 controls also reported the powerful association
between the SNPs on chromosome 9p21 and CAD [31].
The strongest signal was seen at rs1333049, however the
associations were seen for SNPs across >100kb. Then, they
further looked for replication in the German MI family
study which involved 875 MI cases and 1644 controls using
the GeneChip Human Mapping 500K Array Set (Aﬀymetrix)
[32]. The Same locus on chromosome 9p21 (rs1333049)
had the strongest association with CAD in both studies
with the risk increased by 36% per copy of the C allele. Of
the nine loci which were shown to be strongly associated
with CAD, two of these loci were able to replicate in the
German MI study: chromosome 6q25.1 (rs6922269) and
chromosome 2q36.3 (rs2943634). Further, the combined
analysis of the two studies revealed four additional loci
signiﬁcantly associated with CAD: chromosome 1p13.3
(rs599839), 1q41 (rs17465637), 10q11.21 (rs501120) and
15q22.33 (rs17228212). In 2009, they performed another
replication study with 11550 cases with CAD and 11205
controls from 9 European studies [33]. Other than the
9p21 locus, they conﬁrmed signiﬁcant association at 1p13.3
(rs599839), 1q41 (rs3008621) and 10q11.21 (rs501120).
They were not able to show the signiﬁcant association with
6q25.1 and 2q36.3 and there was no evidence for association
with the locus at 15q22.33. The four loci (9p21, 1p13.3, 1q41
and 10q11.21) act independently and cumulatively increased
the risk for CAD by 15% per additional risk allele. The genes
located within or adjacent to the these four loci are listed in
Table 4. The locus at chromosome 1p13.3 has been shown
to be associated with increased plasma LDL cholesterol, and
thus may contribute to CAD development [34–37].
The locus at 10q11.21 lies adjacent to the chemokine (C-
X-C motif) ligand 12 gene (CXCL12)w h i c he n c o d e ss t r o m a l
cell-derived factor-1, a chemokine which plays a important
role in stem-cell homing and regeneration of myocardial
tissue in ischemic cardiomypopathy [38] and in promoting
angiogenesis by recruiting endothelial progenitor cells from
the bone marrow [39]. The SNPs at 1q41 locates within the
melanoma inhibitory activity family, member 3 (MIA3)g e n e
[40].Underlyingmechanismhowthesegeneticlociaﬀectthe
pathogenesis of CAD need to be further investigated.
The meta-analysis of aforementioned three studies [24,
27, 32] and 7 additional case-control studies successfullyInternational Journal of Hypertension 5
Table 3: Representatives of chip-based GWAS of CAD/MI.
Author, year Phenotype No. of cases/controls Chromosomal loci OR
Helgadottir et al. [24] MI 4587/12767 9p21 1.28
McPherson et al. [27] CAD 3505/18745 9p21 1.26 (CCHS study)
9p21 1.16 (CCHS study)
WTCCC [31] CAD 2000/3000 9p21.3 1.47
Samani et al. [32] CAD 2801/4582 9p21.3 1.28 (adjusted German)
6q25.1 1.23 (adjusted German)
2q36.3 1.08 (adjusted German)
1p13.3 1.29
1q41 1.2
10q11.21 1.33
15q22.33 1.21
CAD Consortium, [33] CAD 11550/11205 9p21 1.2
1p13.3 1.13
1p41 1.1
10q11.21 1.11
Clarke et al. [59] CAD 7991/7946 6q26-27 1.51
Table 4:Geneslocatedwithinoradjacenttothelociassociatedwith
CAD/MI.
Chromosome loci Genes
1p33 PSRC1, CELRS2, MYBPHL, SORT1
1q41 MIA3
2q33 WDR12
2q36.3 no recognized genes
3q22.3 MRAS
6p24 PHACTR1
6q25.1 MTHFD1L
6q26-27 LPA
9p21 p16/CDKN2A, p15/CDKN2B, p14/ARF,
MTAP, ANRIL
10q11.21 CXCL12
12q24 3SH2B3
21q22 MRPS6, SLC5A3, KCNE2
replicated the signiﬁcant association between the risk allele
(C) of the lead SNP, rs1333049 at chromosome 9p21 and
risk of CAD (OR = 1.29) [41]. These study have analyzed
primarily on European descent, however, since the allele
frequency diﬀers among the diﬀerent ethnic groups, the
risk of CAD related to the SNPs at 9p21 may diﬀer among
each ethnic group. Since then, the replicated results in
other ethnics such as Chinese, Japanese and Pakistanis are
published and the association of the SNPs at 9p21 with CAD
seems to be consistent among various ethic groups [42–45].
It is noteworthy that the SNPs in 9p21 region are also
found to be associated with variety of diseases such as
ischemic stroke (OR = 1.01–1.21) [46, 47], abdominal aortic
aneurysm (OR = 1.31), intracranial aneurysm (OR = 1.29)
[48], peripheral artery disease (OR = 1.29) [49], incident
heart failure (OR = 1.17) [50], perioperative myocardial
injury after coronary artery bypass graft surgery [51], type
2 diabetes (OR = 1.20) [52, 53].
More recently, the loci other than 9p21 have been shown
to be associated with CAD or MI. Erdmann et al. applied less
stringent statistical thresholds on their GWAS for CAD to
identify any dismissed SNPs with modest eﬀects or low allele
frequencies and they found one new locus on 3q22.3 in mus-
cle RAS oncogene homolog (MRAS)( O R= 1.15), the gene
thought to play an important role in inﬂammation [54, 55].
There is another GWAS which identiﬁed the SNPs in the
gene related to inﬂammation to be associated with MI [56].
TheyfoundﬁveSNPswhichaﬀecteosinophilcountsinblood
in Icelandic population and reported that a nonsynonymous
SNP at 12q24 in SH2B adaptor protein gene (3SH2B3)w a s
associated with MI signiﬁcantly (OR = 1.13).
The GWAS of early-onset MI revealed 9 loci which have
signiﬁcant association [57]. Three of them were newly iden-
tiﬁed in the study: (i) an intergenic region between MRPS6
(mitochondrial ribosomal protein S6), SLC5A3 (solute car-
rier family 5 (sodium/myo-inositol cotransporter), member
3) and KCNE2 (potassium voltage-gated channel, Isk-related
family, member 2) on chromosome 21q22 (OR = 1.19), 6p24
in PHACTR1 (phosphatase and actin regulator 1) (OR =
1.13) and 2q33 in WDR12 (WD repeat domain 12) (OR =
1.17). The mechanism by which genes at these three regions
increases the risk of MI needs to be elucidated. In addition
to the common variant, copy number variations can be
analyzed by SNP chip and there were no common or rare
copy number variations associated with risk of early-onset
MI in this study.
The group from the WTCCC/German MI study further
conducted a genome-wide haplotype association study for6 International Journal of Hypertension
the ﬁrst time and identiﬁed the SLC22A3-LPAL2-LPA gene
cluster on 6q26-27 as a strong susceptibility locus for CAD
(OR = 1.8) [58]. An increased level of Lp(a) lipoprotein is
a classical hereditary risk for CAD. Clarke et al. identiﬁed
three chromosomal regions (6q26-27, 9p21 and 1p13) were
strongly associated with the risk of CAD using the Human
CVD Bead Chip which included 48742 markers relevant to
cardiovascular disease on 6500 subjects. Among them, the
LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the
strongest association. They identiﬁed two LPA variants that
werestronglyassociatedwithbothanincreasedlevelofLp(a)
lipoprotein and an increased risk of CAD (OR = 1.70 and
1.92) [59]. Both variants were strongly associated with a
reduced copy number in LPA kringle IV-type 2 repeats and
an increased level of Lp(a) lipoprotein. After adjustment for
the Lp(a) lipoprotein level, the association between the LPA
genotype score and the risk of CAD was abolished. The
importance of classical risk factor Lp(a) was reemphasized
by the GWAS.
4. Limitation of GWAS
Initially, GWAS have been primarily assessed only on
European descent and the results of these GWAS may not
be applicable to other ethnics due to wide diﬀerence of
distribution of SNPs and allele frequency. Further studies for
various ethnicity need to be done with use of newer chips
which contains 1 million SNPs to increase coverage.
The CAD associated loci have been found in regions
without known gene-encoding loci. Therefore, further stud-
ies will be required to elucidate the exact functional mecha-
nism by which these loci modulate CAD risk.
Utility of genotyping 9p21 for clinical risk assessment
is controversial [60–62]. The odds ratios for CAD risk in
each selected SNPs are small (around 1.2) and explain only
a small proportion of the heritable, genetic component of
susceptibility to the disease. Newer susceptibility loci for
CAD need to be validated with replication studies and in
the future, we should evaluate the genetic risks by combining
multipleindependentcommonvariantssusceptibleforCAD.
TheGWASmethodissupportedbythecommondisease-
common variant hypothesis, which predicts that genetic
variants causing common disease exist frequently, but each
variant only have a small eﬀect on disease susceptibility.
Another hypothesis is the rare variant hypothesis. Rare
variants have a minor allele frequency of less than 1%.
The rare variant hypothesis postulates that common disease
is caused by multiple rare variants which have a strong
causative eﬀect on disease and this hypothesis was conﬁrmed
in colorectal adenomas [63, 64]. Rare variants cannot be
captured by GWAS and requires whole genome sequencing
using next generation sequencing system.
In addition, other types of variants, such as insertion-
deletion variant, block substitution and inversion variant,
so called structural variants may account for important
contributors to the diseases and are also hard to detect by the
chip-basedmethod.Thenextgenerationsequencingmethod
is also helpful to ﬁnd these structural variants.
5. Conclusion
(1) The SNPs Data from the HapMap project and devel-
opment of new chip technology enabled genotyping
large amount of common variants simultaneously
and contributed to eﬃciently identify gene loci
aﬀecting susceptibility to common diseases including
CAD.
(2) The region at 9p21 was shown to be signiﬁcantly
associated with CAD in 2007 and comprehensive
replication across multiple studies provides unequiv-
ocal evidence that this locus is associated with CAD
in European descent. This region is also associated
with abdominal aneurysm, intracranial aneurysm
and type2 diabetes, and seems tobe a veryimportant
region for various diseases.
(3) Sincetheoddsratiosoftheriskalleleat9p21forCAD
aresmall,screeningforthisriskalleleprobablyaﬀects
little, if any, to the each individual’s risk prediction.
Using genomic tests to improve existing risk models
wouldlikelyrequirecombiningtheeﬀectsofmultiple
common genetic variants.
(4) Rare variants and structural variants which cannot
be captured by GWAS need to be searched by whole
genome sequencing.
(5) GWAS approach has identiﬁed novel and unbiased
genetic contributors to CAD and these insights
provide the important direction to better understand
the pathogenesis of CAD and to develop new and
improved preventive measures and treatments for
CAD.
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